Keyphrases
Prognostic Impact
100%
Glucocorticoid Receptor
100%
Myeloma
100%
Multiple Myeloma
100%
Thalidomide
40%
Glucocorticoid Receptor alpha
40%
Steroid Therapy
40%
Hematological Diseases
20%
Progesterone Receptor Expression
20%
Duration of Response
20%
Response to Steroids
20%
Plasma Cell Labeling Index
20%
Serum Albumin
20%
Treatment-seeking Sample
20%
Diminished Expression
20%
B-cell Malignancies
20%
Newly Diagnosed multiple Myeloma
20%
Resistance to Steroids
20%
Number of Patients
20%
Prognostic Factors
20%
Glucocorticoid-induced
20%
Estrogen Receptor Status
20%
β2-microglobulin (β2-MG)
20%
Creatinine
20%
C-reactive Protein
20%
Tumor
20%
Prognostic Significance
20%
Expression Pattern
20%
Bone Marrow
20%
Apoptosis
20%
Splice Variant
20%
Multiple Myeloma Patients
20%
Marrow
20%
Breast Cancer
20%
Hemoglobin
20%
Plasma Cells
20%
Cytotoxicity
20%
Biochemistry, Genetics and Molecular Biology
Glucocorticoid Receptor
100%
Glucocorticoid
100%
Dexamethasone
100%
Immunoglobulin Producing Cell
66%
Beta-2 Microglobulin
33%
Cytogenetics
33%
Cell Labeling
33%
B Cell
33%
Progesterone Receptor
33%
Electrocorticography
33%
Lactate Dehydrogenase
33%
Estrogen Receptor
33%
Cytotoxicity
33%
Serum Albumin
33%
C-Reactive Protein
33%
Creatinine
33%
Programmed Cell Death
33%
Pharmacology, Toxicology and Pharmaceutical Science
Myeloma
100%
Glucocorticoid Receptor
100%
Multiple Myeloma
100%
Glucocorticoid
50%
Dexamethasone
50%
Glucocorticoid Receptor Alpha
33%
Thalidomide
33%
Diseases
33%
C Reactive Protein
16%
Estrogen Receptor
16%
Creatinine
16%
Beta 2 Microglobulin
16%
Breast Cancer
16%
Progesterone Receptor
16%
Neoplasm
16%
Serum Albumin
16%
Lactate Dehydrogenase
16%
Cytotoxicity
16%